Aeterna Zentaris Inc AEZS-CA:Toronto Stock Exchange

*Data is delayed | CAD
Last | 03/05/21 EST
1.18UNCH (UNCH)
Volume
592,294
52 week range
0.37 - 4.63

...

Loading . . .

KEY STATS

  • Open1.19
  • Day High1.21
  • Day Low0.99
  • Prev Close1.18
  • 52 Week High4.63
  • 52 Week High Date02/08/21
  • 52 Week Low0.37
  • 52 Week Low Date11/02/20
  • Market Cap58.47M
  • Shares Out62.68M
  • 10 Day Average Volume448,101.27
  • Dividend-
  • Dividend Yield-
  • Beta2.28
  • 1 Year % Change14.56

RATIOS/PROFITABILITY

  • EPS (TTM)-0.24
  • P/E (TTM)-4.88
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Aeterna Zentaris Inc News

There is no recent news for this security.

Latest AEZS-CA News From Our Partners

February 21, 2021

February 9, 2021

QUOTE FINDER

Profile

MORE
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses...
Carolyn Egbert Ph.D., J.D.
Chairman
Klaus Paulini Ph.D.
President
Leslie Auld
Chief Financial Officer
Nicola Ammer
Vice President
Matthias Gerlach
Vice President
Guenther Grau
Vice President - Finance
Address
315 Sigma Drive
Summerville, SC
29486
United States